Trial Search Results
Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol
This study is designed to provide patients access to theirnonconforming lisocabtagene maraleucel as a treatment option for theirdisease. The study will evaluate the safety and effectiveness of thistherapy through the collection of information.
Stanford is currently accepting patients for this trial.
Juno Therapeutics, a Subsidiary of Celgene
- Biological: Nonconforming Lisocabtagene Maraleucel
1. Subject and/or LAR must understand and voluntarily sign an informed consent form prior
to any study-related assessments/procedures being conducted.
2. Subject has relapsed and/or refractory large B-cell lymphoma and is, per the treating
physician assessment, eligible for treatment with lisocabtagene maraleucel per the
approved prescribing information.
3. Subject is ≥ 18 years of age at the time of signing the informed consent form.
4. Subject had a specific batch of lisocabtagene maraleucel manufactured intended for
commercial treatment; however, the final manufactured product did not meet commercial
5. Remanufacturing (eg, repeat leukapheresis and manufacturing) is deemed not feasible or
clinically inappropriate per assessment of the treating physician in discussion with
6. Subject is clinically stable, has recovered from any toxicities prior to receiving
lymphodepleting chemotherapy, and has adequate bone marrow function to receive
lymphodepleting chemotherapy. The treating physician is advised to contact Medical
Monitor in the event there is any concern regarding administration of lymphodepleting
7. Females of childbearing potential must:
1. Have a negative pregnancy test as verified by the treating physician within 7
days prior to the first dose of lymphodepleting chemotherapy following
institutional testing methodology practices. This applies even if the subject
practices true abstinence from heterosexual contact.
2. Either commit to true abstinence from heterosexual contact or agree to use, and
be able to comply with, effective contraception without interruption.
Contraception methods must include 1 highly effective method from screening until
at least 12 months after the nonconforming lisocabtagene maraleucel
3. Agree to abstain from breastfeeding during study participation and for at least
12 months following nonconforming lisocabtagene maraleucel administration.
4. There are insufficient exposure data to provide any recommendation concerning the
duration of contraception and the abstaining from breastfeeding following
treatment with lisocabtagene maraleucel. Any decision regarding contraception and
breastfeeding after infusion should be discussed with the treating physician.
8. Male subjects must:
1. Practice true abstinence or agree to use a condom during sexual contact with a
pregnant female or a female of childbearing potential for at least 12 months
after nonconforming lisocabtagene maraleucel administration even if the subject
has undergone a successful vasectomy.
2. There are insufficient exposure data to provide any recommendation concerning the
duration of contraception following treatment with lisocabtagene maraleucel. Any
decision regarding contraception after infusion should be discussed with the
9. Subject must agree to not donate blood, organs, tissue, sperm or semen and egg cells
for usage in other individuals for at least 1 year following nonconforming
lisocabtagene maraleucel administration.
1. Subject has a hypersensitivity to the active substance or to any of the excipients.
2. Subject should not experience a significant worsening in clinical status that would,
in the opinion of the treating physician, either increase the risk of adverse events
associated with lymphodepleting chemotherapy, or exclude them from treatment with
nonconforming lisocabtagene maraleucel.
3. Subject has any significant medical condition, laboratory abnormality, or psychiatric
illness, sociologic or geographic condition that would prevent the subject from
participating in the Expanded Access Protocol complying with protocol requirements in
the Investigator's judgement.
4. Subject has any condition and/or laboratory abnormality that places the subject at
unacceptable risk if he/she were to participate in the Expanded Access Protocol based
on the Investigator's judgement
5. Pregnant or nursing women or has intention of becoming pregnant during the study.
6. Subjects with central nervous system (CNS)-only involvement by malignancy (note:
subjects with secondary CNS involvement are allowed on study).
7. Subject has active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
infection at the time of pretreatment evaluation
8. Subject has uncontrolled systemic fungal, bacterial, viral or other infection despite
appropriate antibiotics or other treatment at the time of nonconforming lisocabtagene
9. Subject has presence of acute or chronic graft-versus-host disease (ie, GVHD)
10. Use of the following:
1. Therapeutic doses of corticosteroids (defined as > 20 mg/day prednisone or
equivalent) within 72 hours prior to nonconforming lisocabtagene maraleucel
administration. Physiologic replacement, topical, and inhaled steroids are
2. Low dose chemotherapy (eg, vincristine, rituximab, cyclophosphamide ≤ 300
mg/m2)given after leukapheresis to maintain disease control must be stopped ≥ 7
days prior to lymphodepleting chemotherapy.
3. Cytotoxic chemotherapeutic agents that are not considered lymphotoxic (see below)
within 1 week of LD chemotherapy. Oral chemotherapeutic agents, including
lenalidomide and ibrutinib, are allowed if at least 3 half-lives have elapsed
prior to lymphodepleting chemotherapy.
4. Donor lymphocyte infusions within 6 weeks of nonconforming lisocabtagene
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study